Journal
EXPERT OPINION ON DRUG SAFETY
Volume 14, Issue 5, Pages 777-788Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2015.1017468
Keywords
5-grass pollen tablet; allergic rhinitis; allergic rhinoconjunctivitis; asthma; clinical trial; pollinosis; safety; sensitization; sublingual immunotherapy; tolerability
Categories
Funding
- Stallergenes
Ask authors/readers for more resources
Introduction: The 5-grass pollen tablet (Oralair (R), Stallergenes, Antony, France) is a once-daily preseasonal and coseasonal sublingual immunotherapy (SLIT) that is effective in controlling the symptoms of allergic rhinoconjunctivitis and in reducing the need for symptomatic medication. Areas covered: The body of safety data gathered from the 5-grass pollen tablet clinical development program, post-approval studies, and more than 6 years of real-life experience demonstrates the safety and tolerability profile of the 5-grass pollen tablet across all age groups. Adverse events (AEs) are generally mild or moderate in severity, and rarely lead to treatment discontinuation. AEs also tend to decline in frequency and severity over time and with repeated treatment. The most frequent treatment-emergent AEs are local-site oropharyngeal reactions (e.g., oral pruritus, throat irritation, tongue pruritus, mouth edema, ear pruritus), which are consistent with the sublingual route of administration. Expert opinion: The first dose of the 5-grass pollen tablet should be administered under the supervision of an experienced physician, to allow for optimal monitoring and timely management of AEs, should they occur. The 5-grass pollen tablet can be administered at home after the first dose, and patients and carers should be educated on how to manage adverse reactions, unplanned treatment interruptions and situations in which SLIT should be withheld.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available